Invex Therapeutics (ASX:IXC) Other Long Term Assets: A$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IXC Invex Therapeutics Ltd ASX:IXC
32 GF Score
Price A$0.12
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics Other Long Term Assets?

Invex Therapeutics ASX:IXC +9.52% 32 Other Long Term Assets is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:IXC with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Invex Therapeutics's other long-term assets for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Invex Therapeutics Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Other Long Term Assets Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Long Term Assets
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:IXC
32GF Score
Invex Therapeutics Ltd ASX:IXC
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of A$0.00 Mil mean?
Invex Therapeutics (ASX:IXC) has a Other Long Term Assets of A$0.00 Mil as of Dec. 2025. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Other Long Term Assets too high?
Invex Therapeutics' current Other Long Term Assets is A$0.00 Mil. Overall, Invex Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Other Long Term Assets compare to VRTX and REGN?
Invex Therapeutics' Other Long Term Assets of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Biotechnology company?
A good Other Long Term Assets depends on the Biotechnology industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Other Long Term Assets is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Other Long Term Assets of A$0.00 Mil. The current Other Long Term Assets is A$0.00 Mil. Invex Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Other Long Term Assets is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
32GF Score

Get the complete analysis for ASX:IXC

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.12
Price